Abstract: Pharmaceutical compositions and unit dosage forms comprising Compound (I) are disclosed.

Abstract: Pharmaceutical compositions and unit dosage forms comprising Compound (I) are disclosed.

Abstract: The present invention is directed to processes for making and compositions containing quinolines such as formula I or pharmaceutically acceptable salts thereof wherein: X1 is H, Br, CI, or X2 is H, Br, CI, or n1 is 1-2; and n2 is 1-2.

Abstract: The present invention is directed to processes for making and compositions containing quinolines such as formula I or pharmaceutically acceptable salts thereof wherein: X1 is H, Br, CI, or X2 is H, Br, CI, or n1 is 1-2; and n2 is 1-2.

Abstract: Pharmaceutical compositions and unit dosage forms comprising Compound (I) are disclosed.

Abstract: Pharmaceutical compositions and unit dosage forms comprising Compound (I) are disclosed.

Abstract: The present invention is directed to processes for making and compositions containing quinolines such as formula I or pharmaceutically acceptable salts thereof wherein: X1 is H, Br, CI, or X2 is H, Br, CI, or n1 is 1-2; and n2 is 1-2.

Abstract: Pharmaceutical compositions and unit dosage forms comprising Compound (I) are disclosed.

Abstract: Pharmaceutical compositions and unit dosage forms comprising Compound (I) are disclosed.

Abstract: The present invention is directed to processes for making and compositions containing quinolines such as formula I or pharmaceutically acceptable salts thereof wherein: X1 is H, Br, CI, or X2 is H, Br, CI, or n1 is 1-2; and n2 is 1-2.

Abstract: The present invention is directed to processes for making and compositions containing quinolines such as formula I or pharmaceutically acceptable salts thereof wherein: X1 is H, Br, CI, or X2 is H, Br, CI, or n1 is 1-2; and n2 is 1-2.

Abstract: An anesthetic breast pad includes a polyester panel having a front surface, a rear surface, a continuous peripheral edge and a central aperture for accommodating a wearer's breast nipple. A sectoral notch extending from the peripheral edge to the central aperture allows the aperture and the panel to expand, contract and contort to comfortably adapt to the wearer. On the rear surface of the panel, along the entire peripheral edge, is an adhesive strip for tenuously securing the pad to the wearer. Within the boundary formed by the continuous adhesive strip is a thin sheet pretreated with a topical anesthetic. Accordingly, prior to surgery, a patient adhesively secures the pad to the breast to conveniently apply the anesthetic to the underlying area.

Abstract: Pharmaceutical compositions and unit dosage forms comprising Compound (I) are disclosed.

Abstract: The present invention is directed to processes for making and compositions containing quinolines such as formula I or pharmaceutically acceptable salts thereof wherein: X1 is H, Br, Cl, or X2 is H, Br, Cl, or n1 is 1-2; and n2 is 1-2.

Abstract: Pharmaceutical compositions and unit dosage forms comprising Compound (I) are disclosed.

Abstract: The present invention is directed to processes for making and compositions containing quinolines such as formula I or pharmaceutically acceptable salts thereof wherein: X1 is H, Br, Cl, or X2 is H, Br, Cl, or n1 is 1-2; and n2 is 1-2.

Abstract: An individualized intravenous exogenous insulin-based therapy for infusing insulin intravenously to a subject or a patient to improve impaired hepatic glucose processing. The therapy includes treatment sessions involving the assessment of metabolic factors, forming a subject profile, and matching the subject profile to a diabetic treatment model. Using the diabetic treatment model, a quantity and frequency of intravenous insulin bolus, dosage amounts of magnesium, and dosage amounts of potassium can be calculated. The methods that improve impaired hepatic glucose processing in subjects and patients can simultaneously introduce separated insulin bolus from an insulin reservoir, dosage amounts of magnesium, and dosage amounts of potassium. The subject profile can create a weight management protocol that uses a metabolic enhancement, wherein the individualized intravenous exogenous insulin-based therapy produces a subject or a patient with improved cellular ATP functioning.

Abstract: An individualized intravenous exogenous insulin-based therapy for infusing insulin intravenously to a subject or a patient to improve impaired hepatic glucose processing. The therapy includes treatment sessions involving the assessment of metabolic factors, forming a subject profile, and matching the subject profile to a diabetic treatment model. Using the diabetic treatment model, a quantity and frequency of intravenous insulin bolus, dosage amounts of magnesium, and dosage amounts of potassium can be calculated. The methods that improve impaired hepatic glucose processing in subjects and patients can simultaneously introduce separated insulin bolus from an insulin reservoir, dosage amounts of magnesium, and dosage amounts of potassium. The subject profile can create a weight management protocol that uses a metabolic enhancement, wherein the individualized intravenous exogenous insulin-based therapy produces a subject or a patient with improved cellular ATP functioning.

Abstract: The present invention is directed to processes for making and compositions containing quinolines such as formula I or pharmaceutically acceptable salts thereof wherein: X1 is H, Br, Cl, or X2 is H, Br, Cl, or n1 is 1-2; and n2 is 1-2.